Iacob Speranta, Cicinnati Vito R, Hilgard Philip, Iacob Razvan A, Gheorghe Liana S, Popescu Irinel, Frilling Andrea, Malago Massimo, Gerken Guido, Broelsch Christoph E, Beckebaum Susanne
Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany.
Transplantation. 2007 Jul 15;84(1):56-63. doi: 10.1097/01.tp.0000267916.36343.ca.
Hepatitis C virus (HCV) recurrence after liver transplantation (LT) is almost universal, but the natural history of recurrent HCV in the allograft is highly variable. Our study had two aims: 1) to assess the impact of different pre- and postLT factors on graft and patient survival in HCV transplant recipients and 2) to create a model which may predict the patients at risk for HCV-related graft cirrhosis at 5 years postLT.
A total of 168 LTs were considered for this study. Univariate and multivariate Cox proportional hazards regression model was used, as well as logistic regression analysis to create a model of prediction of HCV cirrhosis within 5 years after LT.
Predictive factors for both decreased graft and patient survival included patients recently transplanted (2000-2004), induction without azathioprine, short-term therapy with mycophenolate mofetil and prednisone (< or =6 months), presence of early cholestasis, histologically proven early recurrence of hepatitis C. Recipient human leukocyte antigen DR3 positivity, presence of early cholestasis, and donor age >50 years were identified as independent predictors of graft cirrhosis within 5 years. A predictive model was established in order to calculate at 6 months a risk score for graft HCV cirrhosis within 5 years postLT using a formula that included the identified independent predictors. The area under receiver operating characteristic curve was 0.83, indicating a good ability to predict medium-term HCV allograft cirrhosis.
This model may be a useful tool for better identifying high-risk HCV patients who should be selected for early initiation of antiviral therapy.
肝移植(LT)后丙型肝炎病毒(HCV)复发几乎是普遍现象,但同种异体移植中复发性HCV的自然病程差异很大。我们的研究有两个目的:1)评估LT前后不同因素对HCV移植受者移植物和患者生存的影响;2)建立一个模型,以预测LT后5年有发生HCV相关移植物肝硬化风险的患者。
本研究共纳入168例肝移植患者。使用单因素和多因素Cox比例风险回归模型,以及逻辑回归分析来建立LT后5年内HCV肝硬化的预测模型。
移植物和患者生存率降低的预测因素包括近期接受移植的患者(2000 - 2004年)、未使用硫唑嘌呤的诱导治疗、霉酚酸酯和泼尼松的短期治疗(≤6个月)、早期胆汁淤积的存在、组织学证实的丙型肝炎早期复发。受者人类白细胞抗原DR3阳性、早期胆汁淤积的存在以及供体年龄>50岁被确定为5年内移植物肝硬化的独立预测因素。建立了一个预测模型,以便在6个月时使用包含已确定独立预测因素的公式计算LT后5年内移植物HCV肝硬化的风险评分。受试者工作特征曲线下面积为0.83,表明具有良好的中期HCV同种异体移植肝硬化预测能力。
该模型可能是一个有用的工具,有助于更好地识别应选择早期开始抗病毒治疗的高风险HCV患者。